Academic Journal
Q1Journal of Crohn s and Colitis
About Journal of Crohn s and Colitis
Journal of Crohn s and Colitis is a scholarly journal published by Oxford University Press. SCImago 2025 places it in Q1 with an SJR of 3.225 and an H-index of 134.
Its listed coverage is 2007-2026 and its research categories include Gastroenterology (Q1); Medicine (miscellaneous) (Q1). The 2025 dataset reports 273 documents and 5029 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Inflammatory Bowel Disease, Microscopic Colitis, Biosimilars and Bioanalytical Methods, Autoimmune and Inflammatory Disorders, Eosinophilic Esophagitis, Diverticular Disease and Complications.
Recent Research Articles
Latest publications matched automatically by ISSN.
Effect of JAK inhibitors on extraintestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease
Marie Truyens, Xenia Tolstoy, Giulio Calabrese, Anneline Cremer et al.
2026-09-03 · DOI: 10.1093/ecco-jcc/jjag129Piezo1 in intestinal epithelial cells plays a critical role in the mechanobiological positive feedback underlying intestinal fibrosis
Xinghuang Liu, Ruohang He, Zhiyue Xu, Xiaochuan Dong et al.
2026-09-03 · DOI: 10.1093/ecco-jcc/jjag103Clinical outcomes following switch from risankizumab to guselkumab in Crohn’s disease
Cong Dai, Yu-Hong Huang
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag119Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression
Mohammad Al Hayek, Maria Manuela Estevinho, Maia Kayal, Osamah Al Hayek et al.
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag111Automated AI-based Mayo Endoscopic Scoring for ulcerative colitis across adult and pediatric cohorts from diverse populations
Kamal Hammouda, Rishi Dakarapu, Chathruckan Rajendra, Hyojeong Lee et al.
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag1222′-Fucosyllactose modulates gut microbiota and systemic metabolism in mild-to-moderate ulcerative colitis: a randomized crossover trial
James M Kennedy, Aminda N De Silva, Patricia Sanz Morales, Carlos G Poveda Turrado et al.
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag120Characterization of remission levels in patients with ulcerative colitis treated with 5-aminosalicylates: results of the cross-sectional CARUC-ASA study by the Belgian IBD Research and Development Group
Catherine Reenaers, Guy Lambrecht, Lieven Pouillon, Filip Baert et al.
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag100Anti-TNF withdrawal or long-term treatment in ulcerative colitis (BIOSTOP): a multicentre open label, randomized controlled trial
Ingrid Prytz Berset, Frode Lerang, Bjørn Moum, Jørgen Jahnsen et al.
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag110Multimodal monitoring of pan-enteric mucosal healing and biologic persistence in Crohn’s disease—the MILESTONE-CD prospective cohort
Offir Ukashi, Ahmad Albshesh, Bella Ungar, Danielle Varon et al.
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag118Modifiable lifestyle factors in early life and inflammatory bowel disease risk in two birth cohorts
Annie Guo, Ida Sigvardsson, Henrik Imberg, Tereza Lerchova et al.
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag114BRD4 contributes to the cytokine-induced acquisition of an IL-13RA2-positive inflammatory fibroblast phenotype
Rachele Frascatani, Mattia Alberto Serra, Andrea Iannucci, Marco Colella et al.
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag128Efficacy, safety, and outcomes of endoscopic submucosal dissection for inflammatory bowel disease-associated colorectal neoplasia: a systematic review and meta-analysis comparing Asian and Western outcomes
Miguel Martins, Maria Vitória Nunes, Guilherme Macedo, Mathieu Pioche et al.
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag082Longitudinal transcriptomic analysis of mucosa in ulcerative colitis after anti-tumor necrosis factor withdrawal compared to continued treatment
Emma Rapp, Ingrid Prytz Berset, Sinan U Umu, Espen Sønderaal Bækkevold et al.
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag121Correction to: Rapid resolution of colon inflammation and microbiome remodeling with vancomycin therapy in a patient with primary sclerosing cholangitis
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag123Management of pediatric Crohn’s disease: an ECCO-ESPGHAN guideline update
Dror S Shouval, Iva Hojsak, Erasmo Miele, Christiane Sokollik et al.
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag084Experience-based reappraisal of the IBD-DCA histopathological scoring system
David Egong, Glen Doherty, Kieran Sheahan
2026-08-05 · DOI: 10.1093/ecco-jcc/jjag131Methotrexate for inflammatory bowel disease: the MICI-METHO multicenter retrospective cohort study
Bénédicte Caron, Julien Kirchgesner, Maria Nachury, Guillaume Bouguen et al.
2026-07-07 · DOI: 10.1093/ecco-jcc/jjag102Methodological and respiratory concerns regarding JAK inhibitor safety in ulcerative colitis
Shan Qingqing
2026-07-07 · DOI: 10.1093/ecco-jcc/jjag109Stability of infliximab serum concentrations during long-term frozen storage: a paired biobank study
Suzanne I Anjie, Sarah van Zon, Karien Bloem, Theo Rispens et al.
2026-07-07 · DOI: 10.1093/ecco-jcc/jjag113Region-specific immune regulation determines differential response to JAK1 inhibition in Crohn’s disease ex vivo
Klaudia Maria Grieger, Susann Dehmel, Valerie Schröder, Kevin Schmidt et al.
2026-07-07 · DOI: 10.1093/ecco-jcc/jjag101Reviews
Community Reviews
Version History
September 8, 2026 at 12:09 am
September 8, 2026